T Schneider1,2, J Chapiro3, M Lin4, J F Geschwind3,5, L Kleinberg6, D Rigamonti7, I Jusué-Torres7, A E Marciscano7, D M Yousem8. 1. Russell H. Morgan Department of Radiology and Radiological Sciences, Division of Neuroradiology, The Johns Hopkins Hospital School of Medicine, Baltimore, MD, 21287, USA. tan.schneider@uke.de. 2. Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany. tan.schneider@uke.de. 3. Russell H. Morgan Department of Radiology and Radiological Sciences, Division of Interventional Radiology, The Johns Hopkins Hospital School of Medicine, Baltimore, MD, 21287, USA. 4. Ultrasound Imaging and Interventions (UII), Philips Research North America, Briarcliff Manor, NY, USA. 5. Department of Radiology and Imaging Science, Yale University School of Medicine, New Haven, CT, USA. 6. Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. 7. Department of Neurological Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. 8. Russell H. Morgan Department of Radiology and Radiological Sciences, Division of Neuroradiology, The Johns Hopkins Hospital School of Medicine, Baltimore, MD, 21287, USA.
Abstract
OBJECTIVES: To determine clinical outcome of patients with vestibular schwannoma (VS) after treatment with fractionated stereotactic radiotherapy (FSRT) and single-session stereotactic radiosurgery (SRS) by using 3D quantitative response assessment on MRI. MATERIALS: This retrospective analysis included 162 patients who underwent radiation therapy for sporadic VS. Measurements on T1-weighted contrast-enhanced MRI (in 2-year post-therapy intervals: 0-2, 2-4, 4-6, 6-8, 8-10, 10-12 years) were taken for total tumour volume (TTV) and enhancing tumour volume (ETV) based on a semi-automated technique. Patients were considered non-responders (NRs) if they required subsequent microsurgical resection or developed radiological progression and tumour-related symptoms. RESULTS: Median follow-up was 4.1 years (range: 0.4-12.0). TTV and ETV decreased for both the FSRT and SRS groups. However, only the FSRT group achieved significant tumour shrinkage (p < 0.015 for TTV, p < 0.005 for ETV over time). The 11 NRs showed proportionally greater TTV (median TTV pre-treatment: 0.61 cm(3), 8-10 years after: 1.77 cm(3)) and ETV despite radiation therapy compared to responders (median TTV pre-treatment: 1.06 cm(3); 10-12 years after: 0.81 cm(3); p = 0.001). CONCLUSION: 3D quantification of VS showed a significant decrease in TTV and ETV on FSRT-treated patients only. NR had significantly greater TTV and ETV over time. KEY POINTS: Only FSRT not GK-treated patients showed significant tumour shrinkage over time. Clinical non-responders showed significantly less tumour shrinkage when compared to responders. 3D volumetric assessment of vestibular schwannoma shows advantages over unidimensional techniques.
OBJECTIVES: To determine clinical outcome of patients with vestibular schwannoma (VS) after treatment with fractionated stereotactic radiotherapy (FSRT) and single-session stereotactic radiosurgery (SRS) by using 3D quantitative response assessment on MRI. MATERIALS: This retrospective analysis included 162 patients who underwent radiation therapy for sporadic VS. Measurements on T1-weighted contrast-enhanced MRI (in 2-year post-therapy intervals: 0-2, 2-4, 4-6, 6-8, 8-10, 10-12 years) were taken for total tumour volume (TTV) and enhancing tumour volume (ETV) based on a semi-automated technique. Patients were considered non-responders (NRs) if they required subsequent microsurgical resection or developed radiological progression and tumour-related symptoms. RESULTS: Median follow-up was 4.1 years (range: 0.4-12.0). TTV and ETV decreased for both the FSRT and SRS groups. However, only the FSRT group achieved significant tumour shrinkage (p < 0.015 for TTV, p < 0.005 for ETV over time). The 11 NRs showed proportionally greater TTV (median TTV pre-treatment: 0.61 cm(3), 8-10 years after: 1.77 cm(3)) and ETV despite radiation therapy compared to responders (median TTV pre-treatment: 1.06 cm(3); 10-12 years after: 0.81 cm(3); p = 0.001). CONCLUSION: 3D quantification of VS showed a significant decrease in TTV and ETV on FSRT-treated patients only. NR had significantly greater TTV and ETV over time. KEY POINTS: Only FSRT not GK-treated patients showed significant tumour shrinkage over time. Clinical non-responders showed significantly less tumour shrinkage when compared to responders. 3D volumetric assessment of vestibular schwannoma shows advantages over unidimensional techniques.
Authors: Jin Kanzaki; Mirko Tos; Mario Sanna; David A Moffat; Edwin M Monsell; Karen I Berliner Journal: Otol Neurotol Date: 2003-07 Impact factor: 2.311
Authors: Patrick C Walz; Matthew L Bush; Zachary Robinett; Claudia F E Kirsch; D Bradley Welling Journal: Otolaryngol Head Neck Surg Date: 2012-05-15 Impact factor: 3.497
Authors: Floriana S Luppino; Edward Grooters; Francisca T de Bruïne; Aeilko H Zwinderman; Andel G L van der Mey Journal: Otol Neurotol Date: 2006-10 Impact factor: 2.311
Authors: O W M Meijer; E J Weijmans; D L Knol; B J Slotman; F Barkhof; W P Vandertop; J A Castelijns Journal: AJNR Am J Neuroradiol Date: 2008-02-22 Impact factor: 3.825
Authors: Julian P Sauer; Thomas M Kinfe; Bogdan Pintea; Andreas Schäfer; Jan P Boström Journal: Strahlenther Onkol Date: 2018-05-23 Impact factor: 3.621
Authors: Mohamed H Khattab; Neil B Newman; David M Wharton; Alexander D Sherry; Guozhen Luo; Nauman F Manzoor; Alejandro Rivas; L Taylor Davis; Lola B Chambless; Albert Attia; Anthony J Cmelak Journal: J Neurol Surg B Skull Base Date: 2019-06-12
Authors: Inpyeong Hwang; Seung Hong Choi; Jin Wook Kim; Eung Koo Yeon; Ji Ye Lee; Roh-Eul Yoo; Koung Mi Kang; Tae Jin Yun; Ji-Hoon Kim; Chul-Ho Sohn Journal: Eur Radiol Date: 2022-01-27 Impact factor: 5.315
Authors: Umberto Tosi; Sergio Guadix; Anjile An; Drew Wright; Paul J Christos; Susan Pannullo; Andrew Brandmaier; Jonathan P S Knisely; Philip E Stieg; Rohan Ramakrishna Journal: Neurooncol Pract Date: 2021-02-01